% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Seum:295913,
      author       = {T. Seum$^*$ and M. Hoffmeister$^*$ and H. Brenner$^*$},
      title        = {{R}isk-{A}dapted {S}tarting {A}ges of {C}olorectal {C}ancer
                      {S}creening for {P}eople {W}ith {D}iabetes or {M}etabolic
                      {S}yndrome.},
      journal      = {Alimentary pharmacology $\&$ therapeutics},
      volume       = {61},
      number       = {4},
      issn         = {0269-2813},
      address      = {Oxford},
      publisher    = {Blackwell Science},
      reportid     = {DKFZ-2024-02726},
      pages        = {675-681},
      year         = {2025},
      note         = {#EA:C070#LA:C070# / 2025 Feb;61(4):675-681},
      abstract     = {Individuals with diabetes and metabolic syndrome have an
                      increased risk of colorectal cancer (CRC), suggesting
                      earlier screening than the average-risk population may be
                      warranted.To derive risk-adapted starting ages of CRC
                      screening for people with diabetes or metabolic syndrome.We
                      determined 5-year cumulative risks of CRC at individual ages
                      between 30 and 50 across Europe (overall and individually
                      for Germany, France, the UK and Italy) and North America
                      (the United States and Canada) based on the GLOBOCAN 2022
                      database. Using risk estimates from meta-analyses
                      (2020-2023), we derived the ages at which individuals with
                      diabetes or metabolic syndrome reach the same CRC risk as
                      the average-risk population at age 50 (aCR50) or 45
                      (aCR45).Individuals with diabetes were estimated to reach
                      aCR50 at age 47 $(95\%$ confidence interval, 45-49) in
                      Europe and 46 (42-49) in North America. For metabolic
                      syndrome, the corresponding ages were 47 (47-48) in Europe
                      and 46 (46-47) in North America. Disparities across
                      countries were minimal, with deviations of up to no more
                      than one year. For screening programmes starting at age 45,
                      corresponding risk-adapted starting ages for people with
                      diabetes or metabolic syndrome were estimated to be 42
                      (41-44) and 43 (42-43) for Europe and 41 (38-44) and 41
                      (41-42) for North America, respectively.People with diabetes
                      or metabolic syndrome reach risk levels comparable to the
                      average risk population three to four years earlier. Our
                      results offer empirical guidance for defining risk-adapted
                      starting ages of CRC screening for these high-risk groups.},
      keywords     = {colorectal cancer (Other) / diabetes (Other) / metabolic
                      syndrome (Other) / risk‐adapted screening (Other)},
      cin          = {C070 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39686687},
      doi          = {10.1111/apt.18435},
      url          = {https://inrepo02.dkfz.de/record/295913},
}